Whilst no trials have been initiated with STGD1 patients, a Phase II trial of 246 patients with age-related macular degeneration (NCT00429936) identified adverse events in 20% of the high-dose cohort (300 mg daily oral dose) for whom treatment was stopped. Here, ABCA4 is linked to age-related macular degeneration.